Roth Capital Comments on Aptevo Therapeutics Inc.’s FY2028 Earnings (NASDAQ:APVO)

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Analysts at Roth Capital issued their FY2028 earnings per share (EPS) estimates for Aptevo Therapeutics in a note issued to investors on Friday, April 19th. Roth Capital analyst J. Aschoff expects that the biotechnology company will earn $2.76 per share for the year. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($57.83) per share.

Separately, StockNews.com initiated coverage on Aptevo Therapeutics in a research report on Thursday, April 18th. They set a “sell” rating for the company.

Aptevo Therapeutics Stock Performance

APVO opened at $0.71 on Monday. Aptevo Therapeutics has a 1-year low of $0.67 and a 1-year high of $91.96. The business has a 50 day moving average price of $4.55 and a two-hundred day moving average price of $7.56.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,235,000 shares of the biotechnology company’s stock, valued at approximately $408,000. Armistice Capital LLC owned about 10.72% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.